Study Medication

ABX-002 is a new investigational medicine that is being studied for the adjunctive treatment of major depressive disorder.

MDD is a heterogenous disorder with numerous potential causes, which may include a combination of neurobiological imbalances, genetics, and other environmental influences. ABX-002 is a potent and selective thyroid hormone beta receptor (TRβ) agonist designed to potentially enhance the CNS benefits of thyroid hormone biology while also aiming to reduce the peripheral liabilities of synthetic thyroid hormone (e.g., triiodothyronine, T3), an unapproved treatment which has shown clinical benefit in numerous placebo-controlled human studies across MDD and bipolar depression. ABX-002 is believed to work on thyroid hormone receptors in the brain and is thought to potentially help improve brain bioenergetics, restore brain connectivity and neuroplasticity, and enhance serotonergic pathways.

ABX-002 is being studied as a once-daily treatment, taken as an oral solution first thing in the morning on an empty stomach.